2022
DOI: 10.1016/j.annonc.2022.03.221
|View full text |Cite
|
Sign up to set email alerts
|

202P Abemaciclib in HR+/Her2- metastatic breast cancer patients after previous progression on palbociclib or ribociclib: Clinical experience in a tertiary hospital in Madrid, Spain

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles